Oric Pharmaceuticals Inc expected to post a loss of 51 cents a share - Earnings Preview

ORIC Pharmaceuticals

02/05/2025 12:37

Oric Pharmaceuticals Inc ORIC.OQ ORIC.O is expected to show no change in quarterly revenue when it reports  results on May 5 (estimated) for the period ending March 31 2025

​LSEG's mean analyst estimate for Oric Pharmaceuticals Inc is for a loss of 51 cents per share.

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 12 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts had risen by about 0.7% in the last three months. ​

Wall Street's median 12-month price target for Oric Pharmaceuticals Inc is $17.00​, above​ its last closing price of $5.57. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATEÂŪ
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Dec. 31 2024
-0.52
-0.51
-0.51
Met
-0.9
Sep. 30 2024
-0.48
-0.48
-0.49
Missed
-2.4
Jun. 30 2024
-0.41
-0.41
-0.45
Missed
-9.2​
Mar. 31 2024
-0.45
-0.44
-0.37
Beat
15.2
​​Dec. 31 2023
-0.49
-0.49
-0.49
Met
-0.7
Sep. 30 2023
-0.46
-0.46
-0.44
Beat
4.7​
Jun. 30 2023
-0.57
-0.57
-0.50
Beat
12.1
Mar. 31 2023
-0.54
-0.54
-0.53
Beat
1.9

This summary was machine generated May 2 at 11:37 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)